a public good project by the
Synthesis
Company
of California

© 2026

William G. Wierda | doi.page

0 works0 citations0 h-index

William G. Wierda

The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)

Publications by Year

Research Areas

Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, Immunodeficiency and Autoimmune Disorders

Most-Cited Works

→ Chimeric antigen receptor T-cell therapy — assessment and management of toxicities(2017)2,299 cited
→ Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia(2013)2,236 cited
→ Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors(2020)2,047 cited
→ Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia(2015)1,860 cited
→ Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia(2015)881 cited
→ Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease(2011)811 cited

→ Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study(2016)

785 cited

→ Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity(2017)785 cited

→ Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma(2017)744 cited

→ KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study(2021)736 cited